⌕
Kazia Therapeutics · KZIA · Nasdaq
Tenet 50 · Mixed
Compare
$5.37−2.19%At closeTenet 50 · Mixed
$5.37−0.12 (−2.19%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Kazia Therapeutics (KZIA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 65% below its peak, net margin −4736.1%.
The lines that matter · FY22–FY26
Revenue ($K)▼51.5%
583.6
FY23→FY26CAGR +236.4%/yr
Net income ($K)▼103.1%
−27,641.3
FY22→FY26CAGR —
Diluted EPS▲70.2%
−0.01
FY22→FY26CAGR —
What the receipts whisper · what a headline number hides
Share count
+0.0%

6.3bn → 6.3bn diluted shares since FY26. Broadly flat, so EPS moves with net income rather than with the share count.

What the income statement says · FY22–FY26
Where every revenue dollar goes · FY26 ($K)583.6Revenue0.0COGS583.6Gross profit−7329.2R&D−14374.2SG&A−21119.8Op income−6521.5Tax & other−27641.3Net income

-4736¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
25390190431269563480%FY22FY26

Over this window: gross 100.0% → 100.0%. Net margin -4736.1% is below the sector median.

The receipt · income statement · FY22–FY26 USD thousands except per-share & ratios · hover a line for its definition
On the latest annual statement the reported earnings per share does not reconcile with net income to common shareholders divided by the reported share count (a factor of 1.589), so the two figures are on different bases. Both are shown as filed.
USD thousands except per-share & ratios
Line itemFY26FY25FY24FY23FY22YoYCAGR 22→26
Revenue & profitability
Revenue
583.61,202.21,656.615.3−69.0▼51.5%+236.4% (23→26)
Cost of revenue
0.00.00.00.00.0——
Gross profit
583.61,202.21,656.615.3−69.0▼51.5%+236.4% (23→26)
Research & development
7,329.24,815.411,604.610,370.313,926.7▲52.2%−14.8%
Selling, general & admin
14,374.25,731.79,056.05,718.93,530.5▲150.8%+42.0%
Total operating expenses
21,703.414,375.820,581.213,831.717,457.2▲51.0%+5.6%
Operating incomefeeds ROC rank
−21,119.8−13,173.6−18,924.6−13,816.4−17,526.3▼60.3%—
Other income, net
−6,521.5−1,581.5864.00.00.0——
Pretax income
−27,641.3−14,755.1−18,060.6−13,816.4−17,526.3▼87.3%—
Income tax
0.0−1,147.6−180.9−180.6−254.1——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−27,641.3−13,607.4−17,879.7−13,635.8−17,272.2▼103.1%—
Per share
Diluted EPSbuyback-sensitive
−0.01−0.02−0.07−0.07−0.13——
Diluted shares (bn)
6.350.810.330.230.14▲684.1%+160.1%
Margins
Gross margin80th pct in Healthcare
100.0%100.0%100.0%100.0%100.0%▲0.0pp+0.0pp
Operating margin
−3618.7%−1095.8%−1142.4%−90155.9%25382.0%▼2522.9pp−29000.7pp
Net margin4th pct in Healthcare
−4736.1%−1131.9%−1079.3%−88977.7%25014.0%▼3604.3pp−29750.1pp
FY16 – FY21 · 6 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-11-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Kazia Therapeutics' revenue last fiscal year?

Kazia Therapeutics reported revenue of $583.6K in fiscal 2026, down 51.5% from fiscal 2025.

What was Kazia Therapeutics' net income?

Kazia Therapeutics reported net income of −$27,641.3K in fiscal 2026, a net margin of −4736.1%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.